Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is a prospective, uncontrolled, multicenter study to evaluate the safety and performance of the NuVasive ACP System in patients who undergo anterior cervical spine surgery. Consecutive patients at a given site who meet eligibility requirements will be asked to consent to participate in the study. These patients will present with pathologic conditions in the cervical spine that are amenable to surgical treatment and will be screened prior to study enrollment. Once enrolled in the study, subjects will undergo anterior cervical spine surgery using the NuVasive ACP System based on th...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients who are ≥18 years of age at the time of consent
- 2. Have planned anterior cervical (C2 to C7) spine surgery using the NuVasive ACP System in conjunction with a NuVasive interbody implant or vertebral body replacement device (VBR), or a structural bone allograft spacer, for treatment of any of the following conditions:
- • 1. degenerative disc disease, as defined by neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies
- • 2. trauma (including fractures)
- • 3. tumors involving the cervical spine
- • 4. cervical spinal deformity (kyphosis, lordosis, or scoliosis)
- • 5. failed previous cervical fusion(s) (e.g., pseudoarthrosis)
- • 6. cervical spondylolisthesis
- • 7. cervical spinal stenosis
- • 3. Able to undergo surgery based on physical exam, medical history, and surgeon judgment
- • 4. Understands the conditions of enrollment and is willing to sign an informed consent form to participate in the study
- Exclusion Criteria:
- • 1. Procedures performed with interbody implants with integrated vertebral body screw(s)
- • 2. Patient is involved in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested)
- • 3. Use of bone growth stimulators postoperatively
- • 4. Active smoking within 6 weeks of surgery
- • 5. Patient has known sensitivity to materials implanted
- • 6. Systemic or local infection (latent or active) or signs of local inflammation
- • 7. Patient has inadequate bone stock or quality, or a physical or medical condition that would prohibit beneficial surgical outcome based on surgeon judgment
- • 8. Pregnant, or plans to become pregnant
- • 9. Patient is a prisoner
- • 10. Patient is participating in another clinical study that would confound study data
About Nuvasive
NuVasive is a leading medical device company specializing in innovative solutions for spine surgery. Committed to advancing surgical techniques and improving patient outcomes, NuVasive develops cutting-edge technologies and products that enhance the efficiency and effectiveness of spinal procedures. The company’s focus on research and development, combined with a robust clinical trial portfolio, underscores its dedication to evidence-based practices and continuous improvement in the field of spinal healthcare. Through collaboration with healthcare professionals and a commitment to education, NuVasive aims to transform the landscape of spine surgery and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbia, Missouri, United States
Wilmington, North Carolina, United States
Naperville, Illinois, United States
Patients applied
Trial Officials
Kyle Malone, MS
Study Director
Globus Medical Inc
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials